Patent classifications
C07D491/20
DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY
Provided herein are compounds of the Formula (I), (II), and (III):
##STR00001##
as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.
DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY
Provided herein are compounds of the Formula (I), (II), and (III):
##STR00001##
as well as pharmaceutically acceptable salts thereof, wherein the substituents are those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of oncologic diseases.
Compounds for coordinating with a metal, compositions containing such compounds, and methods of catalyzing reactions
A compound capable of coordinating with a metal includes a chemical structure as shown in claim 1, in which: EPD represents a group having an electron pair donor atom; B and B′ are each independently an aryl group, a heteroaryl group, an alkenyl group, or alkynyl group, or B and B′ form a spirocyclic group; and R.sub.1, R.sub.2, and R.sub.3 are selected from various substituents.
Compounds for coordinating with a metal, compositions containing such compounds, and methods of catalyzing reactions
A compound capable of coordinating with a metal includes a chemical structure as shown in claim 1, in which: EPD represents a group having an electron pair donor atom; B and B′ are each independently an aryl group, a heteroaryl group, an alkenyl group, or alkynyl group, or B and B′ form a spirocyclic group; and R.sub.1, R.sub.2, and R.sub.3 are selected from various substituents.
Dihydrochromene derivatives
The present invention relates to the compound of formula (I) wherein R.sup.1A, R.sup.1B, R.sup.1C, and R.sup.1D are hydrogen atom, etc., R.sup.2A and R.sup.2B are hydrogen atom, etc., R.sup.3A, R.sup.3B, R.sup.3C, and R.sup.3D are hydrogen atom, etc., L is bond, etc., V is C.sub.1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents. ##STR00001##
Dihydrochromene derivatives
The present invention relates to the compound of formula (I) wherein R.sup.1A, R.sup.1B, R.sup.1C, and R.sup.1D are hydrogen atom, etc., R.sup.2A and R.sup.2B are hydrogen atom, etc., R.sup.3A, R.sup.3B, R.sup.3C, and R.sup.3D are hydrogen atom, etc., L is bond, etc., V is C.sub.1-6 alkylene, Q is optionally-substituted imidazole, or a pharmaceutically acceptable salt thereof, as a novel anti-tumor agent that targets CSCs which are thought to be closely involved in the persistent proliferation of malignant tumor, metastasis or recurrence of cancer, and resistance to anti-tumor agents. ##STR00001##
Compositions and methods for the treatment of xerostomia
The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV and formula V and the methods for the treatment of xerostomia may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral mucosal inflammatory, dry mouth or oral dry mouth mediated infectious diseases.
Spirocyclic Heterocycle Compounds Useful as HIV Integrase Inhibitors
The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
##STR00001##
Spirocyclic Heterocycle Compounds Useful as HIV Integrase Inhibitors
The present invention relates to Spirocyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined herein. The present invention also relates to compositions comprising at least one Spirocyclic Heterocycle Compound, and methods of using the Spirocyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
##STR00001##
COMPOUNDS, COMPOSITIONS, AND METHODS
The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.